Publications by authors named "Michitoshi Yabe"

Claim this Profile
A
Association of FDG-PET/CT findings with adequate tissue samples for gene panel testing in transbronchial lung biopsy and endobronchial ultrasound-guided transbronchial needle aspiration.
Akiko Tamura, Ryo Ko, Hirotsugu Kenmotsu, Takuya Kawata, Suguru Matsuda, Michitoshi Yabe

Respir Investig· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.
Michitoshi Yabe, Tateaki Naito, Suguru Matsuda, Meiko Morita, Motoki Sekikawa

Thorac Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deterioration of performance status before administration of chemotherapy as a prognostic factor in untreated advanced non-small cell lung cancer.
Kenju Ando, Hirotsugu Kenmotsu, Yuichiro Nishibori, Akiko Tamura, Suguru Matsuda, Michitoshi Yabe

Cancer Treat Res Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study.
Yuichiro Nishibori, Hirotsugu Kenmotsu, Kenju Ando, Ayumi Tonsho, Suguru Matsuda, Michitoshi Yabe

Cancer Treat Res Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute exacerbation of combined pulmonary fibrosis and emphysema due to suspected loxoprofen-induced lung injury.
Masaru Ando, Honoka Nagase, Yoshio Satonaga, Izumi Yamatani, Michitoshi Yabe

Geriatr Gerontol Int· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study.
Noboru Morikawa, Tateaki Naito, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Michitoshi Yabe

J Geriatr Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.
Kosei Doshita, Tateaki Naito, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Michitoshi Yabe

Thorac Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Meiko Morita, Akira Ono, Motoki Sekikawa, Kosei Doshita, Keita Miura, Michitoshi Yabe

Cancer Rep (Hoboken)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of anamorelin among patients with diabetes.
Kenju Ando, Tateaki Naito, Satoshi Hamauchi, Keita Miura, Yuichiro Nishibori, Michitoshi Yabe

Int J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer.
Yuko Iida, Kazushige Wakuda, Takuya Kawata, Meiko Morita, Motoki Sekikawa, Michitoshi Yabe

Thorac Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed iliopsoas abscess following COVID-19 pneumonia.
Ryuichiro Takaki, Masaru Ando, Yoshio Satonaga, Michitoshi Yabe, Takamasa Kan

Respir Investig· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty]).
Masaru Ando, Yoshio Satonaga, Ryuichiro Takaki, Michitoshi Yabe, Takamasa Kan

Int J Infect Dis· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer.
Naoya Nishioka, Tateaki Naito, Taichi Miyawaki, Michitoshi Yabe, Kosei Doshita

Thorac Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
Ari Nishimura, Akira Ono, Kazushige Wakuda, Takanori Kawabata, Michitoshi Yabe

Invest New Drugs· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer.
Ari Nishimura, Akira Ono, Kazushige Wakuda, Takanori Kawabata, Michitoshi Yabe

Invest New Drugs· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer.
Taichi Miyawaki, Tateaki Naito, Michitoshi Yabe, Hiroaki Kodama, Naoya Nishioka

Support Care Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
Taichi Miyawaki, Hirotsugu Kenmotsu, Michitoshi Yabe, Hiroaki Kodama, Naoya Nishioka

Invest New Drugs· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors.
Kazushige Wakuda, Michitoshi Yabe, Hiroaki Kodama, Naoya Nishioka, Taichi Miyawaki

Jpn J Clin Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.
Hiroaki Kodama, Hirotsugu Kenmotsu, Takanori Kawabata, Akifumi Notsu, Michitoshi Yabe

Cancer Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Hiroaki Kodama, Kazushige Wakuda, Michitoshi Yabe, Naoya Nishioka, Eriko Miyawaki

Invest New Drugs· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
Nobuaki Mamesaya, Koji Muramatsu, Michitoshi Yabe, Hiroaki Kodama, Naoya Nishioka

Int J Clin Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Kazushige Wakuda, Michitoshi Yabe, Hiroaki Kodama, Naoya Nishioka, Taichi Miyawaki

Lung Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis